Why Light Protection and Dry Granulation Dominate Oxytetracycline HCl Tablet Manufacturing

Oxytetracycline hydrochloride (CAS 2058-46-0) is a yellow, water-soluble tetracycline API whose solid-state stability profile imposes constraints that begin at incoming raw-material handling and persist through film coating. The molecule is susceptible to photodecomposition and moisture-activated epimerization; therefore, a direct compression process is normally rejected at formulation screening unless a fully light-protected facility and near-zero moisture atmosphere can be maintained. The compliance framework for a compressed tablet begins with the current Ph. Eur. monograph for oxytetracycline hydrochloride and the corresponding USP monograph, with release testing anchored to identity by infrared absorption spectrophotometry under Ph. Eur. 2.2.24, loss on drying under Ph. Eur. 2.2.32, related substances by liquid chromatography, and residue on ignition under the compendial method. Finished-tablet testing invokes uniformity of dosage units USP <905> / Ph. Eur. 2.9.40, dissolution USP <711> / Ph. Eur. 2.9.3 with a method and acceptance criterion defined in the marketing authorisation, disintegration USP <701>, and friability USP <1216>. Elemental impurity control follows ICH Q3D, residual solvents ICH Q3C, and photostability ICH Q1B. On the addition-ratio side, a representative uncoated core for a 250 mg oxytetracycline base-equivalent tablet falls in the total mass window of 400–600 mg, with the hydrochloride salt occupying 45–65% w/w. The high API fraction leaves room for microcrystalline cellulose at 20–35% w/w, croscarmellose sodium at 2–5% w/w, a povidone K30 binder in granulating solution at 3–5% w/w, and magnesium stearate at 0.5–1.5% w/w; the lubricant level must remain tight because tetracycline salts exhibit sticking tendencies on steel tooling when the lubricant film is depleted during long compression runs. Downstream processing typically moves through roller compaction rather than wet granulation, using roll force in the 5–15 kN/cm range and granulation through a 1.0–1.4 mm screen to preserve ribbon porosity without compromising tabletability. Compression on a rotary press operates with a punch force of 10–20 kN and target hardness 80–150 N, with friability held below 1.0%; tablets are then film-coated with a light-blocking aqueous Opadry system containing titanium dioxide and iron oxide, at a weight gain of 2–4% w/w, to meet photoprotection obligations. The terminal product classes are immediate-release film-coated tablets of 250 mg and 500 mg strength in aluminium or PVC/PVDC blister packaging, stored at not more than 25 °C and protected from light.

Where dose titration across a 250 mg to 500 mg range favours encapsulation rather than compression, the unit operation shifts from ribbon compaction to low-shear powder filling, and the dominant risk is no longer tabletability but capsule shell moisture transfer and powder flooding. Hard gelatin or HPMC capsule shells are equilibrium-moisture materials; when shell moisture drops below roughly 10–12% at low relative humidity, brittleness causes splitting during high-speed filling, whereas relative humidity above 55–60% softens the shell and accelerates API hydrolysis in the fill. Manufacturing areas are therefore held at 40–50% RH and 20–25 °C. The formulation addition ratio moves the API fraction upward relative to a tablet because no binder dilution is needed: a representative 250 mg capsule fill has a total fill mass of 320–420 mg, with oxytetracycline hydrochloride at 60–75% w/w, lactose monohydrate or mannitol at 15–25% w/w, pregelatinized starch at 5–10% w/w, croscarmellose sodium at 2–4% w/w, and sodium stearyl fumarate at 1–2% w/w in place of magnesium stearate to avoid over-lubrication and delayed dissolution. Downstream equipment includes a bin blender for low-shear mixing, a conical mill for deagglomeration, and a dosator or tamping-pin encapsulator configured for size 0 or size 1 shells; fill weight is maintained by periodic check-weighing and compaction-force feedback, while powder moisture is held at 1–3% as determined by USP <921> or Ph. Eur. 2.5.12. The compliance envelope mirrors the tablet pathway for uniformity of dosage units USP <905>, dissolution USP <711>, disintegration USP <701>, elemental impurities ICH Q3D, and residual solvents ICH Q3C. Terminal product types are immediate-release hard gelatin or HPMC capsules in 250 mg and 500 mg strengths, packed with silica-gel desiccant in amber glass or foil-laminated blisters; a desiccant is mandatory if capsule shell and API moisture-transfer data show an upward drift beyond 3% during stability chamber testing at 40 °C/75% RH.

Granule Porosity and Reconstitution Time in Oral Suspension Manufacture

Oral suspension granules differ from compressed-tablet intermediates in that the target performance attribute is not compaction survival but rapid, residue-free reconstitution into a uniform suspension in potable water. Published data for this specific formulation configuration is limited, so process design relies on fluid-bed granulation trials that measure granule porosity, bulk density, and reconstitution time under the target bottle volume. The compliance framework for a human oral suspension is derived from the current Ph. Eur. monograph for oxytetracycline hydrochloride, the general dosage-form requirements for non-sterile oral liquids, and finished-product testing that includes uniformity of dosage units Ph. Eur. 2.9.40, microbial enumeration Ph. Eur. 2.6.12/2.6.13, and moisture determined by USP <921>. The addition ratio for a powder intended to deliver 125 mg oxytetracycline per 5 mL after reconstitution places the API at 8–15% w/w in the dry granule, with sucrose or maltodextrin as the large-volume carrier at 60–75% w/w, sodium citrate dihydrate at 1–3% w/w as a buffering and complexation moderator, xanthan gum at 0.2–0.5% w/w as a suspending agent, colloidal silicon dioxide at 0.2–0.5% w/w, and flavour or sweetener at 1–3% w/w. Downstream processing is performed in a top-spray fluid-bed granulator with an aqueous binder solution; inlet air is controlled at 55–65 °C, product temperature at 30–38 °C, atomising air pressure at 1.5–2.5 bar, and final granule moisture at 0.5–2.0%. The dried granule is screened to retain a particle-size window of approximately 200–850 µm, because larger granules delay reconstitution and smaller fines segregate during bottle filling. Terminal product types include 60 mL and 100 mL bottles of powder for oral suspension delivering 125 mg/5 mL after reconstitution, as well as unit-dose sachets. Reconstitution water quality must be specified, because carbonate-hard water above approximately 250 mg/L as CaCO₃ can reduce solubility and bioavailability through tetracycline-cation chelation; the label and technical data sheet should state the permitted potable-water hardness and the beyond-use date for the reconstituted suspension, commonly assigned at 7 days under refrigerated storage at 2–8 °C.

When Dissolved Oxygen Accelerates Colour Degradation in Injectable Solutions

In aqueous injectable manufacturing, dissolved oxygen and metal-ion redox cycling are the primary degradation accelerants for oxytetracycline hydrochloride, so the process is engineered as an aseptic nitrogen-protected solution rather than a terminal-sterilised product. The API concentration is typically expressed as base-equivalent strength: 50 mg/mL and 100 mg/mL solutions correspond to roughly 5% w/v and 10% w/v of the hydrochloride salt, though exact salt-to-base conversion must use the batch potency factor obtained from the API certificate of analysis, typically ≥95.0% on the dried basis. A representative small-volume injectable formula includes water for injection as solvent, a buffering/alkalising agent such as sodium hydroxide or tromethamine to raise the pH from the intrinsic acidic region of 2.0–3.0 to a final target of 8.0–9.0, and, where the marketing authorisation permits, a reducing agent such as sodium formaldehyde sulfoxylate at levels not exceeding 0.3% w/v to maintain colour. The manufacturing sequence begins with water for injection cooled to 15–20 °C, sparged with pharmaceutical-grade nitrogen until dissolved oxygen is ≤1 mg/L, and held under nitrogen overlay during complete dissolution. The bulk solution is sterile-filtered through a 0.22 µm PVDF or PES filter; terminal steam sterilisation is avoided because thermal degradation produces epioxytetracycline and anhydrotetracycline species that shift the impurity profile outside the compendial related-substances limit. Filling occurs in a Grade A environment under EU GMP Annex 1 into sterile Type I glass vials with halogenated butyl rubber closures; contact surfaces are restricted to 316L stainless steel and silicone to avoid iron, copper, and aluminium ions that form coloured chelates. Release testing includes sterility USP <71>, bacterial endotoxins USP <85>, subvisible particulate matter USP <788>, visible particulates USP <790>, pH by Ph. Eur. 2.2.3, colour and clarity by Ph. Eur. 2.2.1/2.2.2, assay by liquid chromatography, elemental impurities ICH Q3D, and sterility assurance parameters under 21 CFR 211.113. Terminal product types include 10 mL, 50 mL, and 100 mL single-dose or multidose vials for intramuscular or intravenous administration according to the approved label; a multidose format must additionally meet antimicrobial effectiveness testing under USP <51>.

A water-soluble oral powder intended for drinking-water administration imposes constraints on particle-size distribution and dissolution rate that are largely absent from solid dosage forms for human use. Oxytetracycline hydrochloride is selected in this application because the salt provides rapid aqueous solubility, but the same property means that moisture ingress during storage can convert the free-flowing powder into a caked, non-dispensing mass. The addition ratio for a veterinary oral powder is commonly set at 10–20% w/w oxytetracycline hydrochloride on a carrier such as lactose monohydrate or anhydrous dextrose, with sodium citrate or citric acid at 1–3% w/w to buffer the final drinking-water solution and colloidal silicon dioxide at 0.2–0.5% w/w as a flow aid; the carrier fraction typically occupies 75–85% w/w. Finished use concentrations are not a formulation property but a label condition: drinking-water administration may target 100–500 mg/L depending on species, body weight, water consumption, and the authorised veterinary medicinal product instruction, and no API-addition ratio can substitute for that label-controlled dilution calculation. Downstream processing consists of low-shear ribbon or V-blending under 30–40% RH, followed by a milling or deagglomeration step to keep the maximum particle size below 500 µm and the median particle size in the 150–250 µm band; this particle-size window balances rapid dissolution in drinking water against dusting and segregation in multi-dose pouches. The powder is filled into foil-lined heat-sealed pouches or high-density polyethylene jars with induction-seal liners, with desiccant where the pack is exposed to tropical humidity. The applicable compliance framework for non-sterile veterinary oral powders includes 21 CFR 211 GMP obligations, VICH GL18 for residual solvents where relevant, and the current Ph. Eur. monograph for oxytetracycline hydrochloride for API quality; finished-product release testing commonly includes moisture USP <921>, fill weight, identity, assay by high-performance liquid chromatography, and microbial enumeration Ph. Eur. 2.6.12/2.6.13. Terminal product types include 100 g, 500 g, and 1 kg oral powder packs for drinking-water administration in poultry, swine, and ruminants, labelled with withdrawal periods and a prohibition on use in animals producing milk for human consumption where required by the local marketing authorisation.